Atorvastatin: pharmacological characteristics and lipid-lowering effects (Q36957795)

17 August 2017

1 reference

title

Atorvastatin: pharmacological characteristics and lipid-lowering effects (English)

1 reference

17 August 2017

Andrea Poli

1

1 reference

17 August 2017

1 January 2007

1 reference

17 August 2017

1 reference

17 August 2017

67 Suppl 1

1 reference

17 August 2017

3-15

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200767001-00002

17 August 2017

0 references

cites work

Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies

1 reference

12 December 2020

LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study

1 reference

12 December 2020

High-dose atorvastatin after stroke or transient ischemic attack

1 reference

12 December 2020

Identifying patients for aggressive cholesterol lowering: the risk curve concept

1 reference

12 December 2020

Comparative effects of lipid-lowering therapies

1 reference

12 December 2020

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

1 reference

12 December 2020

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

1 reference

12 December 2020

Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy

1 reference

12 December 2020

Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy

1 reference

12 December 2020

Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins

1 reference

12 December 2020

The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy

1 reference

12 December 2020

Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal

1 reference

12 December 2020

New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism

1 reference

12 December 2020

Evidence-based goals versus achievement in clinical practice in secondary prevention of coronary heart disease: findings in EUROASPIRE II.

1 reference

12 December 2020

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

1 reference

12 December 2020

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with p

1 reference

12 December 2020

Statin inhibition of HMG-CoA reductase: a 3-dimensional view

1 reference

12 December 2020

Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study

1 reference

12 December 2020

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study

1 reference

12 December 2020

Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy

1 reference

12 December 2020

A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin

1 reference

12 December 2020

Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study

1 reference

12 December 2020

Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin

1 reference

12 December 2020

Metabolism and excretion of atorvastatin in rats and dogs

1 reference

12 December 2020

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

1 reference

12 December 2020

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

12 December 2020

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

1 reference

12 December 2020

Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.

1 reference

12 December 2020

Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions

1 reference

12 December 2020

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

12 December 2020

Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia

1 reference

12 December 2020

Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients

1 reference

12 December 2020

A brief review paper of the efficacy and safety of atorvastatin in early clinical trials

1 reference

12 December 2020

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

1 reference

12 December 2020

Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3.

1 reference

12 December 2020

Natural statins and stroke risk.

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Early statin treatment following acute myocardial infarction and 1-year survival

1 reference

12 December 2020

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

1 reference

12 December 2020

The evolving role of statins in the management of atherosclerosis

1 reference

12 December 2020

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

12 December 2020

Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators

1 reference

12 December 2020

Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin.

1 reference

12 December 2020

A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study

1 reference

12 December 2020

Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group

1 reference

12 December 2020

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

1 reference

12 December 2020

10.2165/00003495-200767001-00002

Identifiers

DOI

1 reference

PubMed ID

17910517

Dimensions Publication ID

17 August 2017

0 references

1 reference

PubMed ID

17910517